Antiviral effect – Page 19 – Communicable Diseases Research

Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China

Pharmacology

Published on 2021-02-252022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus

글루코실세라마이드 합성효소 억제제는 SARS-CoV-2 및 인플루엔자 바이러스의 복제를 방지합니다

Accelerated Communication

Published on 2021-02-252022-09-10
Journal: The Journal of Biological Chemistry [Category] 비임상, 신종인플루엔자,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analogue antiviral drugs Antiviral effect antiviral therapies breath caused CC50, cytotoxicity concentration 50% cell membranes Cerdelga clinical trials component coronavirus COVID-19 COVID-19 pandemic CPE, cytopathic effect creating cross DENV, dengue virus dependency disrupt DMSO, dimethyl sulfoxide DNJ, deoxynojirimycin drug Drug administration DsiRNA, Dicer-substrate siRNA examined food GCS, glucosylceramide synthase GlcCer, glucosylceramide global health glucosylceramide glucosylceramide synthase GZ-161, GENZ-667161 GZ-346, Genz-123346 H1N1 Health host cell host cell membrane host cell membranes Infection Influenza Influenza virus inhibit inhibitor life cycle life cycles limit LSD, lysosomal storage disease MDCK, Madin–Darby Canine Kidney membrane MOI, multiplicity of infection NB-DNJ, N-butyl–DNJ not applicable outcomes Phase III clinical trials PR8, influenza virus A/PR/8/34 (H1N1) Prevent Replication replication of SARS-CoV-2 respiratory SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome Coronavirus SI, selective index specific inhibitor specific inhibitors sphingolipids Support synthesis the United State therapeutic target Treatment United States Vaccine venglustat Viral viral life cycle virus viruses
[DOI] 10.1016/j.jbc.2021.100470 PMC 바로가기 [Article Type] Accelerated Communication

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities

Review

Published on 2021-02-252022-10-28
Journal: Pharmaceutics [Category] COVID-19,

Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies

프로폴리스, 꿀벌 꿀 및 그 구성 요소는 코로나바이러스 질병 2019(COVID-19)로부터 보호합니다: In Silico, In Vitro 및 임상 연구에 대한 검토

Review

Published on 2021-02-252022-09-10
Journal: Molecules [Category] MERS, 임상, 치료제,

[키워드] ACE-II activities Anti-inflammatory antioxidant Antiviral antiviral drug Antiviral effect Antiviral treatment bee bee honey bee products caffeic acid clinical Combination component Compound coronavirus disease Coronavirus disease 2019 Coronaviruses COVID -19 COVID-19 cytokine Cytokine storm discharge Effect Effects examined exhibited Express fatality flavonoids green Honey hospital hospitalized COVID-19 patient hospitalized COVID-19 patients host cells immune immunomodulatory in silico in vitro inhibit inhibited less Liposome Luteolin main protease molecular docking/biochemical modeling molecular simulations Mortality naringin natural Nigella Sativa non-structural protein non-structural proteins Prophylactic Propolis randomized clinical trials receiving Remdesivir respiratory review rutin SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome spike glycoprotein standard care Symptom the cytokine storm these compound these compounds Treatment treatment for COVID-19 Treatment outcome Trigger Vero E6 VERO E6 cells Viral viral clearance viral replication viral spike viral-host interaction virulence
[DOI] 10.3390/molecules26051232 PMC 바로가기 [Article Type] Review

The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

Research Article

Published on 2021-02-242022-10-31
Journal: Evidence-based Complementary and Alternative Medicine : eCAM [Category] COVID-19,

Observational study of haloperidol in hospitalized patients with COVID-19

코로나19로 입원한 환자를 대상으로 한 할로페리돌의 관찰 연구

Clinical Trial

Published on 2021-02-192022-08-13
Journal: PLoS ONE [Category] MERS, 임상, 치료제,

[키워드] 48 hour 48 hours 95% CI Admission Adult patients analyses Analysis antipsychotic Antiviral effect AP-HP assistance association baseline Characteristics Composite COVID-19 death defined discharge home discharged home dose endpoints examined finding Follow-up haloperidol Hospital admission hospitalized patient hospitals In-vitro Inpatient intubation multicenter observational study multiple sensitivity analyses multivariable Cox regression observational study occurred outcome over Paris Patient patients hospitalized patients with COVID-19 PCR test per day positive COVID-19 primary end-point primary endpoint Probability psychotropic medications receiving receptor receptor antagonist Result risk SARS-CoV-2 secondary endpoint Sensitivity analyses suggested survivor univariate Cox regression university Weighting with COVID-19
[DOI] 10.1371/journal.pone.0247122 PMC 바로가기 [Article Type] Clinical Trial

Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates Covid-19-Induced Metabolic Disturbances

Cardiovascular Medicine

Published on 2021-02-172022-10-31
Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19,

Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19

Immunology

Published on 2021-02-122022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] accelerated alteration Antiviral effect application autophagy Azithromycin benefit clearance Clinical use contribute Course COVID-19 COVID-19 immune response COVID-19 pandemic Cytokine storm death defined early stage Effect effective Efficacy Evidence Factor function identify immune mechanism immune response immunomodulation immunomodulatory immunomodulatory effect immunomodulatory therapy immunosuppressive Infection Inflammation inflammatory cell infiltration investigated late stage Lung pathology macrophages mechanism Multiple neutrophil patients patients with COVID-19 Potential pro-inflammatory cytokine progression pursuit Regulatory severe disease shown Stage Support the disease therapeutic therapy viral burden virus while
[DOI] 10.3389/fimmu.2021.574425 PMC 바로가기 [Article Type] Immunology

Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial

신종 코로나바이러스에 대항하는 직접 항바이러스제: 아지스로마이신(DAWn-AZITHRO), 무작위, 다기관, 공개 라벨, 적응형, SARS-CoV-2에 대해 작용하는 새로운 항바이러스제의 개념 증명 임상 시험 - 아지스로마이신 시험

Study Protocol

Published on 2021-02-092022-09-10
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 7-category ordinal scale adaptive Admission amplify antibiotic Antiviral Antiviral effect Azithromycin Belgium blunt Bronchoalveolar lavage Care chance chest CT scan clinical Clinical improvement clinical trial coronavirus SARS-CoV-2 Course COVID COVID-19 COVID-19 disease cytokine cytokine signaling decrease defined diagnosed with COVID-19 Diagnosis Direct discharge disease disease course drug Efficacy eligible EudraCT feature health regulations Hospitalized hospitalized patient hospitalized patients Hydroxychloroquine hyperinflammatory state immunomodulatory properties implicated in vitro include Inclusion Intervention life Local Macrolide medical need multicenter name Nasopharyngeal swab National Novel coronavirus novel coronavirus SARS-CoV-2 Open-label Ordinal Scale pathway Pathways Patient patients patients with COVID-19 PCR Phase 2 Primary outcome proof-of-concept clinical trial radiological Randomized Randomized controlled trial receive recruit SARS-CoV-2 severe COVID-19 disease shown Standard Standard of care study inclusion supplementary material Support sustained symptomatic the disease the WHO treatment effect treatment effects treatment group treatment strategy Trial Viral viral replication widespread with COVID-19
[DOI] 10.1186/s13063-021-05033-x PMC 바로가기 [Article Type] Study Protocol

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Research

Published on 2021-02-042022-10-05
Journal: Molecular Psychiatry [Category] SARS, 임상, 진단, 치료제,

[키워드] 95% CI adjusted adults hospitalized Analysis Antiviral effect AP-HP association biological marker Characteristics conducted COVID-19 Cox model death depressive disease severity disorder Endpoint epithelial cell examined Hospital admission hospitalized patient hospitals In-vitro Infection inhibit intubation lower risk medication Meta-analysis multicenter multiple sensitivity analyses multivariable Paris Patient patients hospitalized plasma Prevent primary analysis primary endpoint pro-inflammatory mediators Probability psychotropic medications randomized clinical trial recent reduced reduced risk remained retrospective cohort study SARS-CoV-2 severe COVID-19 university Weighting
[DOI] 10.1038/s41380-021-01021-4 [Article Type] Research